Dengue en un neonato

Arteaga‐Livias, Kovy; Bonilla-Crispin, Angela; Panduro-Correa, Vicky; Martínez-Enríquez, Carlos; Dámaso-Mata, Bernardo

doi:10.4067/s0716-10182017000500494

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prevention is based on immunization and vector control, with proper disposal of solid waste and improved water storage practices to prevent female mosquitoes from laying eggs. 5 In April 2023, the National Drug, Food and Technology Administration of Argentina (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, ANMAT) approved the use of a dengue vaccine developed by Japanese pharmaceutical company Takeda, for individuals aged 4 years and older, whether or not they suffered from dengue fever before. The vaccine is called TAK-003.…”

Section: Discussionmentioning

confidence: 99%

Dengue fever in a 32-day-old patient. A rare case report

2024

Arch Argent Pediat

View full text Add to dashboard Cite

Dengue fever is a viral disease transmitted by the Aedes aegypti mosquitoes.In Argentina, dengue fever is an epidemic disease; most cases are reported during the hot months. Until epidemiological week (EW) 20/2023, 106 672 cases were reported across 18 of the 24 provinces of Argentina. Children younger than 2 years are among the main groups at risk. Recognizing signs and symptoms and identifying risk factors is fundamental for the management of cases at a higher risk of severity.Here we describe the case of a 32-day-old female patient who was hospitalized due to febrile syndrome without a source, who had a differential diagnosis of viral meningitis and sepsis and progressed to leukocytosis, thrombocytopenia, hypoalbuminemia in association with rash and edema. The diagnosis of dengue fever was established based on clinical, epidemiological, and positive IgM data.

show abstract

Section: Discussionmentioning

confidence: 99%

Dengue fever in a 32-day-old patient. A rare case report

2024

Arch Argent Pediat

View full text Add to dashboard Cite

show abstract

“…La prevención se sustenta en la inmunización y el control vectorial, con la eliminación adecuada de los residuos sólidos y la mejora de las prácticas de almacenamiento de agua, para evitar que los mosquitos hembras depositen sus huevos. 5 La Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) aprobó en abril de 2023 el uso de la vacuna contra el dengue desarrollada por el laboratorio japonés Takeda para mayores de 4 años, hayan cursado o no previamente la enfermedad. El nombre de la vacuna es TAK-003.…”

Section: Discussionunclassified

Dengue en paciente de 32 días de vida. Reporte de un caso poco habitual

2024

Arch Argent Pediat

View full text Add to dashboard Cite

El dengue es una enfermedad viral transmitida por la picadura del mosquito Aedes aegypti.El comportamiento del dengue en Argentina es epidémico; la mayoría de los casos se observan en los meses de mayor temperatura. Hasta la semana epidemiológica (SE) 20/2023, se registraron en Argentina 106 672 casos; se vieron afectadas 18 de las 24 provincias que conforman el país. Dentro de los principales grupos de riesgo, se incluyen los menores de 2 años. Reconocer los signos, síntomas e identificar los factores de riesgo es fundamental para el manejo de casos con mayor riesgo de gravedad.Presentamos el caso de una paciente de 32 días de vida que se internó por síndrome febril sin foco, con diagnósticos diferenciales de meningitis viral y sepsis, evolucionó con leucocitosis, plaquetopenia, hipoalbuminemia, asociado a exantema y edemas. Se llegó al diagnóstico de dengue por la clínica, epidemiologia e IgM positiva.

show abstract

“…Intrauterine growth restriction, premature placental detachment, preterm birth, miscarriage, and stillbirth have been associated with maternal infection [ 2 , 10 , 17 ]. Vertical transmission is thought to occur with infections in later pregnancy and yield varied manifestations in the neonate, ranging from subclinical infections to dengue hemorrhagic fever and dengue shock syndrome [ 18 , 19 ]. Prior DENV infections have shown protective effects against ZIKV congenital infection in human studies; however, animal models have demonstrated an enhanced risk of congenital transmission in this scenario [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Perinatal dengue and Zika virus cross-sectional seroprevalence and maternal-fetal outcomes among El Salvadoran women presenting for labor-and-delivery

Lynn,

Aquino,

Rivas

et al. 2024

matern health, neonatol and perinatol

View full text Add to dashboard Cite

Background Despite maternal flavivirus infections’ linkage to severe maternal and fetal outcomes, surveillance during pregnancy remains limited globally. Further complicating maternal screening for these potentially teratogenic pathogens is the overwhelming subclinical nature of acute infection. This study aimed to understand perinatal and neonatal risk for poor health outcomes associated with flaviviral infection during pregnancy in El Salvador. Methods Banked serologic samples and clinical results obtained from women presenting for labor and delivery at a national referent hospital in western El Salvador March to September 2022 were used for this study. 198 samples were screened for dengue and Zika virus IgM, and statistical analyses analyzed demographic and clinical outcome associations with IgM positivity. Results This serosurvey revealed a high rate of maternal flavivirus infection—24.2% of women presenting for labor and delivery were dengue or Zika virus IgM positive, suggesting potential infection within pregnancy. Specifically, 20.2% were Zika virus IgM positive, 1.5% were dengue virus IgM positive, and 2.5% were both dengue and Zika virus IgM positive. Women whose home had received mosquito abatement assistance within the last year by the ministry of health were 70% less likely to test IgM positive (aOR = 0.30, 95%CI: 0.10, 0.83). Further, statistical geospatial clustering revealed transmission foci in six primary municipalities. Pregnancy complications and poor birth outcomes were noted among the dengue and/or Zika virus maternal infection group, although these outcomes were not statistically different than the seronegative group. None of the resulting neonates born during this study were diagnosed with congenital Zika syndrome. Conclusions The high rate of Zika virus detected among pregnant women and the lack of Zika-specific neonatal outcomes monitoring during a non-outbreak year highlights the need for continued surveillance in Central America and among immigrant mothers presenting for childbirth from these countries. As changing climatic conditions continue to expand the range of the disease vector, asymptomatic screening programs could be vital to early identification of outbreaks and clinical management of cases.

show abstract

Dengue en un neonato

Cited by 6 publications

References 17 publications

Dengue fever in a 32-day-old patient. A rare case report

Dengue fever in a 32-day-old patient. A rare case report

Dengue en paciente de 32 días de vida. Reporte de un caso poco habitual

Perinatal dengue and Zika virus cross-sectional seroprevalence and maternal-fetal outcomes among El Salvadoran women presenting for labor-and-delivery

Contact Info

Product

Resources

About